Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Chlamydia Diagnostics Market Snapshot

The global chlamydia diagnostics market garnered a market value of US$ 1.17 Billion in 2022 and is expected to accumulate a market value of US$ 3.69 Billion by registering a CAGR of 11% in the forecast period 2023 to 2033. Growth of the chlamydia diagnostics market can be attributed to increasing awareness, technological advancements, and growing demand for early disease diagnosis. the market for chlamydia diagnostics registered a CAGR of 8% in the historical period 2018 to 2022

Chlamydia diagnostics refer to the tests and procedures used to identify the presence of Chlamydia trachomatis bacteria in a person's body. Chlamydia is a sexually transmitted infection (STI) that can be asymptomatic, meaning a person may not show any symptoms but still be infected. Therefore, diagnosing chlamydia is important to prevent the spread of the infection and to start treatment early.

The most common diagnostic method for chlamydia is a nucleic acid amplification test (NAAT), which detects the genetic material of the Chlamydia trachomatis bacteria. This test can be performed on a urine sample or a swab taken from the genital area. Other diagnostic methods may include culture tests or antigen tests, but these are less commonly used.

Report Attribute Details
Expected Market Value (2023) US$ 1.30 Billion
Anticipated Forecast Value (2033) US$ 3.69 Billion
Projected Growth Rate (2023 to 2033) 11% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Chlamydia Diagnostics Market Demand Analysis vs. Forecast 2023 to 2033

According to market research and competitive intelligence provider Future Market Insights- the market for Chlamydia diagnostics reflected a value of 8% during the historical period, 2018 to 2022.

The growth in the market was primarily driven by factors such as the increasing prevalence of chlamydia infections, growing awareness and initiatives for early disease diagnosis, and technological advancements in diagnostic testing.

Furthermore, North America held the largest share of the chlamydia diagnostics market in 2018, followed by Europe and Asia-Pacific. The high prevalence of sexually transmitted infections (STIs) in North America, coupled with the presence of advanced healthcare infrastructure, is expected to drive the growth of the chlamydia diagnostics market in the region.

Thus, the market for Chlamydia diagnostics is expected to register a CAGR of 11% in the forecast period 2023 to 2033.

Which are Some Prominent Drivers of Chlamydia Diagnostics Market?

Increasing prevalence of chlamydia infections favoring market growth

Chlamydia is one of the most common sexually transmitted infections (STIs) worldwide, with an estimated 131 Billion new cases each year. The growing prevalence of chlamydia infections is driving the demand for diagnostic tests to identify the infection early.

Increased awareness about the importance of early diagnosis and treatment of STIs is driving the demand for diagnostic tests, including those for chlamydia. Additionally, government and non-governmental organizations are implementing various initiatives to increase awareness about STIs and promote early disease diagnosis.

The development of new and advanced diagnostic tests for chlamydia, such as nucleic acid amplification tests (NAATs), has improved the accuracy and reliability of chlamydia diagnostics. Additionally, point-of-care testing (POCT) for chlamydia is becoming increasingly popular due to its ease of use and rapid results.

The availability of home testing kits for chlamydia is increasing, which is driving the demand for chlamydia diagnostics. Home testing kits are convenient and offer privacy to patients, which is particularly important for STI testing.

Personalized medicine, which involves tailoring medical treatment to an individual's specific needs, is becoming increasingly popular. Diagnostic tests, including those for chlamydia, are an important tool in personalized medicine, allowing healthcare providers to identify the infection early and tailor treatment to the individual.

Availability of diagnostics tools shaping the landscape for chlamydia diagnostics market

Nucleic acid amplification tests (NAATs): NAATs are the most accurate and sensitive tests for chlamydia diagnostics. These tests detect the genetic material (DNA or RNA) of the Chlamydia trachomatis bacteria in a patient's urine or swab sample.

Enzyme-linked immunosorbent assay (ELISA): ELISA is a type of blood test that detects the presence of antibodies against the Chlamydia trachomatis bacteria in a patient's blood.

Direct fluorescent antibody (DFA) test: DFA is a laboratory test that involves staining the Chlamydia trachomatis bacteria with fluorescent dyes, making them visible under a microscope.

Nucleic acid hybridization tests: These tests detect the presence of the Chlamydia trachomatis bacteria by using probes that bind to specific DNA or RNA sequences of the bacteria.

Culture tests: Culture tests involve growing the Chlamydia trachomatis bacteria in a laboratory culture, which can take several days. This test is less commonly used due to its lower sensitivity and longer turnaround time.

Point-of-care tests (POCTs): POCTs are rapid diagnostic tests that can provide results within minutes. These tests can be performed in a clinic or doctor's office and are usually based on antigen detection or NAAT technology.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Faced by the Chlamydia Diagnostics Market?

Lack of awareness about STIs along with cost of diagnostic tests derailing market growth of chlamydia diagnostics market

There is still a lack of awareness among the general population about sexually transmitted infections (STIs) such as chlamydia, which leads to underdiagnosis and undertreatment of the infection. Limited access to healthcare services, particularly in developing countries, can hinder the growth of the chlamydia diagnostics market. This can limit the availability of diagnostic tests and prevent patients from receiving appropriate treatment.

The cost of diagnostic tests for chlamydia can be a barrier for some patients, particularly in low-income settings. This can lead to delayed diagnosis and treatment of the infection, which can have serious health consequences. The stigma associated with STIs can prevent some individuals from seeking testing and treatment. This can further contribute to the underdiagnosis and undertreatment of chlamydia.

The emergence of antibiotic-resistant strains of Chlamydia trachomatis is a growing concern, as this can limit the effectiveness of antibiotics in treating the infection. Currently, there are no effective vaccines against chlamydia. The lack of a vaccine hinders efforts to prevent the spread of the infection and reduces the focus on the development of diagnostic tests.

Region-Wise Insights

Growing awareness about STIs Contributing to Market Growth of Chlamydia Diagnostics Market in North America?

Inclination towards early diagnosis creating lucrative opportunities of chlamydia diagnostics market

The North America chlamydia diagnostics market is a significant segment of the global chlamydia diagnostics market. North America includes countries such as the United States and Canada, and it is considered one of the leading markets for chlamydia diagnostics.

Factors driving the growth of the North America chlamydia diagnostics market include the increasing prevalence of chlamydia infections, growing awareness about STIs and the importance of early diagnosis, and the availability of advanced diagnostic technologies.

The United States is the largest market for chlamydia diagnostics in North America. The growth is attributed to factors such as the high prevalence of chlamydia infections in the country, the availability of advanced diagnostic technologies, and the presence of major market players. Thus, North America is expected to possess 48% market share for chlamydia market share in 2023.

Advancements in technology Driving Market Growth of Chlamydia Diagnostics Market in Europe?

Development of advanced diagnostic technologies bolstering market growth of chlamydia diagnostics in Europe

Chlamydia is one of the most commonly reported sexually transmitted infections in Europe. The increasing prevalence of chlamydia is driving the demand for chlamydia diagnostic tests in the region. The increasing awareness about sexually transmitted infections, including chlamydia, is leading to more individuals seeking testing and treatment. This is driving the growth of the chlamydia diagnostics market in Europe.

The development of advanced diagnostic technologies, such as molecular diagnostics tests, has led to the development of more accurate and sensitive chlamydia diagnostic tests. This is also driving the growth of the market. The increasing healthcare expenditure in Europe is leading to more investments in healthcare infrastructure, including diagnostic facilities. This is driving the growth of the chlamydia diagnostics market as more individuals have access to testing and treatment.

Point-of-care testing for chlamydia is becoming increasingly popular due to its rapid and easy-to-use nature. This is driving the growth of the point-of-care testing segment in the market. Thus, Europe is expected to possess 46% market share for chlamydia market share in 2023.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-Wise Insights

High sensitivity and specificity for Chlamydia Increasing dependency on NAAT Test for Chlamydia Testing?

Faster results making NAAT a likeable choice for chlamydia diagnostics

There are several types of tests available for the diagnosis of chlamydia, including nucleic acid amplification tests (NAATs), enzyme immunoassays (EIAs), direct fluorescent antibody (DFA) tests, and culture tests.

In recent years, nucleic acid amplification tests (NAATs) have become the most popular type of test for chlamydia diagnostics. NAATs have a high sensitivity and specificity for chlamydia and can detect the presence of the bacterial DNA in a patient's urine, swab, or blood sample. They are also considered to be more reliable than other types of tests, such as culture tests, which can be time-consuming and have a lower sensitivity.

Furthermore, NAATs can be performed using various types of samples, such as urine, vaginal swabs, and rectal swabs, making them a convenient and non-invasive option for patients. Additionally, some NAATs can provide results within a few hours, which is much faster than traditional culture tests that can take several days to yield results. Overall, due to their high accuracy, ease of use, and rapid results, NAATs have become the most popular type of test for chlamydia diagnostics in recent years. Thus, by test type, NAATs are expected to possess 49% market share for chlamydia market share in 2023.

Market Competition

Key players in the chlamydia diagnostics market are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Hologic, Inc., Quidel Corporation, DiaSorin SpA Becton, Dickinson and Company, Bio-Rad Laboratories, Pfizer, Inc., AstraZeneca and Teva Pharmaceuticals

  • Abbott has developed RealTime Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) assay: The Abbott RealTime CT/NG assay is a nucleic acid amplification test (NAAT) that is designed to detect the DNA of both Chlamydia trachomatis and Neisseria gonorrhoeae in various clinical samples, such as urine, swabs, and endocervical samples. The assay is highly sensitive and specific and has been widely adopted by clinical laboratories for chlamydia and gonorrhea testing.
  • Roche has collaborated with NICE to develop guidelines for the use of molecular diagnostic tests for chlamydia and gonorrhea. These guidelines have helped to standardize the use of chlamydia and gonorrhea diagnostic tests in the United kingdom

Report Scope

Report Attribute Details
Market Value in 2023 US$ 1.30 Billion
Market Value in 2033 US$ 3.69 Billion
Growth Rate CAGR of 11% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in USD Billion and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered
  • Test Type
  • End User
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa
Key Countries Profiled
  • USA
  • Canada
  • Brazil
  • Mexico
  • Rest of Latin America
  • Germany
  • United kingdom
  • France
  • Spain
  • Italy
  • Rest of Europe
  • India
  • Malaysia
  • Singapore
  • Thailand
  • Rest of South Asia
  • China
  • Japan
  • South Korea
  • Austria
  • New Zealand
  • GCC countries
  • South Africa
  • Israel
  • Rest of MEA
Key Companies Profiled
  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd
  • Hologic, Inc.
  • Quidel Corporation
  • DiaSorin SpA
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories
  • Pfizer, Inc.
  • AstraZeneca
  • Teva Pharmaceuticals
Customization Available Upon Request

Key Segments Profiled in the Chlamydia Diagnostics Industry Survey

Test Type:

  • Culture Tests
  • Nucleic Acid Amplification Tests (NAAT)
  • Direct Fluorescent Antibody Tests
  • Serology Tests

End User:

  • Hospitals
  • Clinics
  • Diagnostic Centres

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Frequently Asked Questions

What is the Current Valuation of the Chlamydia Diagnostics Market?

The market is expected to reach US$ 1.30 billion in 2023.

What are the Current Trends Driving the Chlamydia Diagnostics Market?

Development of rapid and point-of-care tests and the use of molecular diagnostic techniques for accuracy.

What is the Projected Growth Rate of the Chlamydia Diagnostics Market?

The market is likely to record a growth of 11% from 2023 to 2033.

Which Diagnostic Methods are Leading the Chlamydia Diagnostics Market?

Nucleic acid amplification tests (NAATs) and rapid antigen tests are leading methods.

Which Region is Navigating Toward Growth?

North America is the leading marker for chlamydia diagnostics.

Table of Content

1. Executive Summary | Chlamydia Diagnostics Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Test Type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Test Type, 2023 to 2033

        5.3.1. Culture Tests

        5.3.2. Nucleic Acid Amplification Tests (NAAT)

        5.3.3. Direct Fluorescent Antibody Tests

        5.3.4. Serology Tests

    5.4. Y-o-Y Growth Trend Analysis By Test Type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Test Type, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-User

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By End-User, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-User, 2023 to 2033

        6.3.1. Hospitals

        6.3.2. Clinics

        6.3.3. Diagnostic Centres

    6.4. Y-o-Y Growth Trend Analysis By End-User, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By End-User, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Europe

        7.3.4. South Asia

        7.3.5. East Asia

        7.3.6. Oceania

        7.3.7. MEA

    7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        8.2.1. By Country

            8.2.1.1. USA

            8.2.1.2. Canada

        8.2.2. By Test Type

        8.2.3. By End-User

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Test Type

        8.3.3. By End-User

    8.4. Key Takeaways

9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Test Type

        9.2.3. By End-User

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Test Type

        9.3.3. By End-User

    9.4. Key Takeaways

10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Germany

            10.2.1.2. United kingdom

            10.2.1.3. France

            10.2.1.4. Spain

            10.2.1.5. Italy

            10.2.1.6. Rest of Europe

        10.2.2. By Test Type

        10.2.3. By End-User

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Test Type

        10.3.3. By End-User

    10.4. Key Takeaways

11. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. India

            11.2.1.2. Malaysia

            11.2.1.3. Singapore

            11.2.1.4. Thailand

            11.2.1.5. Rest of South Asia

        11.2.2. By Test Type

        11.2.3. By End-User

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Test Type

        11.3.3. By End-User

    11.4. Key Takeaways

12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. China

            12.2.1.2. Japan

            12.2.1.3. South Korea

        12.2.2. By Test Type

        12.2.3. By End-User

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Test Type

        12.3.3. By End-User

    12.4. Key Takeaways

13. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. Australia

            13.2.1.2. New Zealand

        13.2.2. By Test Type

        13.2.3. By End-User

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Test Type

        13.3.3. By End-User

    13.4. Key Takeaways

14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. GCC Countries

            14.2.1.2. South Africa

            14.2.1.3. Israel

            14.2.1.4. Rest of MEA

        14.2.2. By Test Type

        14.2.3. By End-User

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Test Type

        14.3.3. By End-User

    14.4. Key Takeaways

15. Key Countries Market Analysis

    15.1. USA

        15.1.1. Pricing Analysis

        15.1.2. Market Share Analysis, 2022

            15.1.2.1. By Test Type

            15.1.2.2. By End-User

    15.2. Canada

        15.2.1. Pricing Analysis

        15.2.2. Market Share Analysis, 2022

            15.2.2.1. By Test Type

            15.2.2.2. By End-User

    15.3. Brazil

        15.3.1. Pricing Analysis

        15.3.2. Market Share Analysis, 2022

            15.3.2.1. By Test Type

            15.3.2.2. By End-User

    15.4. Mexico

        15.4.1. Pricing Analysis

        15.4.2. Market Share Analysis, 2022

            15.4.2.1. By Test Type

            15.4.2.2. By End-User

    15.5. Germany

        15.5.1. Pricing Analysis

        15.5.2. Market Share Analysis, 2022

            15.5.2.1. By Test Type

            15.5.2.2. By End-User

    15.6. United kingdom

        15.6.1. Pricing Analysis

        15.6.2. Market Share Analysis, 2022

            15.6.2.1. By Test Type

            15.6.2.2. By End-User

    15.7. France

        15.7.1. Pricing Analysis

        15.7.2. Market Share Analysis, 2022

            15.7.2.1. By Test Type

            15.7.2.2. By End-User

    15.8. Spain

        15.8.1. Pricing Analysis

        15.8.2. Market Share Analysis, 2022

            15.8.2.1. By Test Type

            15.8.2.2. By End-User

    15.9. Italy

        15.9.1. Pricing Analysis

        15.9.2. Market Share Analysis, 2022

            15.9.2.1. By Test Type

            15.9.2.2. By End-User

    15.10. India

        15.10.1. Pricing Analysis

        15.10.2. Market Share Analysis, 2022

            15.10.2.1. By Test Type

            15.10.2.2. By End-User

    15.11. Malaysia

        15.11.1. Pricing Analysis

        15.11.2. Market Share Analysis, 2022

            15.11.2.1. By Test Type

            15.11.2.2. By End-User

    15.12. Singapore

        15.12.1. Pricing Analysis

        15.12.2. Market Share Analysis, 2022

            15.12.2.1. By Test Type

            15.12.2.2. By End-User

    15.13. Thailand

        15.13.1. Pricing Analysis

        15.13.2. Market Share Analysis, 2022

            15.13.2.1. By Test Type

            15.13.2.2. By End-User

    15.14. China

        15.14.1. Pricing Analysis

        15.14.2. Market Share Analysis, 2022

            15.14.2.1. By Test Type

            15.14.2.2. By End-User

    15.15. Japan

        15.15.1. Pricing Analysis

        15.15.2. Market Share Analysis, 2022

            15.15.2.1. By Test Type

            15.15.2.2. By End-User

    15.16. South Korea

        15.16.1. Pricing Analysis

        15.16.2. Market Share Analysis, 2022

            15.16.2.1. By Test Type

            15.16.2.2. By End-User

    15.17. Australia

        15.17.1. Pricing Analysis

        15.17.2. Market Share Analysis, 2022

            15.17.2.1. By Test Type

            15.17.2.2. By End-User

    15.18. New Zealand

        15.18.1. Pricing Analysis

        15.18.2. Market Share Analysis, 2022

            15.18.2.1. By Test Type

            15.18.2.2. By End-User

    15.19. GCC Countries

        15.19.1. Pricing Analysis

        15.19.2. Market Share Analysis, 2022

            15.19.2.1. By Test Type

            15.19.2.2. By End-User

    15.20. South Africa

        15.20.1. Pricing Analysis

        15.20.2. Market Share Analysis, 2022

            15.20.2.1. By Test Type

            15.20.2.2. By End-User

    15.21. Israel

        15.21.1. Pricing Analysis

        15.21.2. Market Share Analysis, 2022

            15.21.2.1. By Test Type

            15.21.2.2. By End-User

16. Market Structure Analysis

    16.1. Competition Dashboard

    16.2. Competition Benchmarking

    16.3. Market Share Analysis of Top Players

        16.3.1. By Regional

        16.3.2. By Test Type

        16.3.3. By End-User

17. Competition Analysis

    17.1. Competition Deep Dive

        17.1.1. Abbott Laboratories

            17.1.1.1. Overview

            17.1.1.2. Product Portfolio

            17.1.1.3. Profitability by Market Segments

            17.1.1.4. Sales Footprint

            17.1.1.5. Strategy Overview

                17.1.1.5.1. Marketing Strategy

        17.1.2. F. Hoffmann-La Roche Ltd

            17.1.2.1. Overview

            17.1.2.2. Product Portfolio

            17.1.2.3. Profitability by Market Segments

            17.1.2.4. Sales Footprint

            17.1.2.5. Strategy Overview

                17.1.2.5.1. Marketing Strategy

        17.1.3. Hologic, Inc.

            17.1.3.1. Overview

            17.1.3.2. Product Portfolio

            17.1.3.3. Profitability by Market Segments

            17.1.3.4. Sales Footprint

            17.1.3.5. Strategy Overview

                17.1.3.5.1. Marketing Strategy

        17.1.4. Quidel Corporation

            17.1.4.1. Overview

            17.1.4.2. Product Portfolio

            17.1.4.3. Profitability by Market Segments

            17.1.4.4. Sales Footprint

            17.1.4.5. Strategy Overview

                17.1.4.5.1. Marketing Strategy

        17.1.5. DiaSorin SpA

            17.1.5.1. Overview

            17.1.5.2. Product Portfolio

            17.1.5.3. Profitability by Market Segments

            17.1.5.4. Sales Footprint

            17.1.5.5. Strategy Overview

                17.1.5.5.1. Marketing Strategy

        17.1.6. Becton, Dickinson and Company

            17.1.6.1. Overview

            17.1.6.2. Product Portfolio

            17.1.6.3. Profitability by Market Segments

            17.1.6.4. Sales Footprint

            17.1.6.5. Strategy Overview

                17.1.6.5.1. Marketing Strategy

        17.1.7. Bio-Rad Laboratories

            17.1.7.1. Overview

            17.1.7.2. Product Portfolio

            17.1.7.3. Profitability by Market Segments

            17.1.7.4. Sales Footprint

            17.1.7.5. Strategy Overview

                17.1.7.5.1. Marketing Strategy

        17.1.8. Pfizer, Inc.

            17.1.8.1. Overview

            17.1.8.2. Product Portfolio

            17.1.8.3. Profitability by Market Segments

            17.1.8.4. Sales Footprint

            17.1.8.5. Strategy Overview

                17.1.8.5.1. Marketing Strategy

        17.1.9. AstraZeneca

            17.1.9.1. Overview

            17.1.9.2. Product Portfolio

            17.1.9.3. Profitability by Market Segments

            17.1.9.4. Sales Footprint

            17.1.9.5. Strategy Overview

                17.1.9.5.1. Marketing Strategy

        17.1.10. Teva Pharmaceuticals

            17.1.10.1. Overview

            17.1.10.2. Product Portfolio

            17.1.10.3. Profitability by Market Segments

            17.1.10.4. Sales Footprint

            17.1.10.5. Strategy Overview

                17.1.10.5.1. Marketing Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

Recommendations

Healthcare

Genital Herpes Treatment Market

Published : June 2023

Healthcare

Herpes Labialis Treatment Market

Published : April 2023

Healthcare

Sexually Transmitted Diseases Diagnostics Market

Published : May 2022

Explore Healthcare Insights

View Reports

Chlamydia Diagnostics Market